1
|
Downs BM, Cope LM, Fackler MJ, Cho S, Wolff AC, Regan MM, Sukumar S, Umbricht CB. Abstract P5-12-04: A new method of data analysis to derive DNA methylation signatures that stratify risk of recurrence in triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancer (TNBC) accounts for 10-17% of all breast cancer and is more likely to be of higher histological grade, poorly differentiated, associated with a higher recurrence rate and with decreased overall survival. The clinical course of a TNBC patient remains difficult to predict, as tumors with homogenous morphological characteristics may vary in response to therapy and have divergent outcomes. Therefore, additional analytical methods are needed to better classify TNBC. Our goal is to refine the analysis of methylome datasets to derive reliable molecular signatures that can distinguish TNBC patients with good outcomes who may benefit from less aggressive treatment, from those with poor outcomes who would be candidates for more aggressive treatments.
Methods: Our laboratory has conducted and reported, in this meeting, results from analysis of 450k methylation array data on a discovery set of 53 high-risk TNBC cases and 62 low-risk controls treated by locoregional therapy alone, as well as 5 normal breast tissue samples. High-risk cases were defined as patients that relapsed within 0.5 to 6.5 years from the time of diagnosis, while low-risk controls had no relapse and >4 year recurrence-free intervals (RFI). In this work, we devised and applied a novel methylation biomarker discovery program named Hypermethylated Outlier Detector (HOD) that emphasizes the selection of highly methylated markers in cases compared to controls, to find a high-risk signature in the TNBC discovery set. The methylation signature identified by HOD was interrogated in a test set of 50 TNBCs (with 16 recurrences) that did not receive chemotherapy, and in a second test set of 131 TNBCs (with 33 recurrences) that did receive chemotherapy.
Results: HOD identified 39 hypermethylated markers (beta >0.20) that could accurately distinguish between the high-risk cases and the low-risk controls in the discovery set of TNBCs (n=115) treated with locoregional therapy alone. In the test set of TNBC (n=50) with no chemotherapy the 39 markers distinguished high from low risk individuals (likelihood ratio test P=0.049). In a second test set of TNBC (n=131) that received chemotherapy the 39 hypermethylated markers again distinguished high from low risk individuals (likelihood ratio test P=0.0043).
Conclusions: We have presented evidence that a methylation signature identified by HOD can be used to identify TNBC patients that have a high-risk of relapse regardless of receiving chemotherapy. This methylation signature could potentially be used to inform physician decisions on therapeutic strategies for TNBC patients. This could ultimately lead to less aggressive treatment given to patients possessing a methylation profile consistent with a better prognosis. Conversely, patients with hypermethylation in the 39 markers will likely benefit from a more aggressive course of treatment.
Citation Format: Downs BM, Cope LM, Fackler MJ, Cho S, Wolff AC, Regan MM, Sukumar S, Umbricht CB. A new method of data analysis to derive DNA methylation signatures that stratify risk of recurrence in triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-04.
Collapse
Affiliation(s)
- BM Downs
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - LM Cope
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - MJ Fackler
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - S Cho
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - AC Wolff
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - MM Regan
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - S Sukumar
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| | - CB Umbricht
- Johns Hopkins University School of Medicine, Baltimore, MD; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
2
|
Fackler MJ, Downs BM, Mercado-Rodriguez C, Cimino-Mathews A, Chen C, Yuan J, Cope LM, Kohlway A, Kocmond K, Lai E, Weidler J, Visvanathan K, Umbricht CB, Harvey S, Wolff AC, Bates M, Sukumar S. Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-03-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Underdeveloped countries reported 882,900 new cases of breast cancer and 324,000 deaths in 2012, likely to be a gross underestimation according to recent reports. Often, mammography screening is not available, primary care services are limited, and pathology and treatment services are available only in the regional hospitals. Because of the lack of access to diagnostic and treatment services, it is estimated that more than 90% of patients with breast cancer never present for medical treatment. To address this situation, an accurate, easy-to-perform diagnostic test appropriate for use in remote clinics is desperately needed. Johns Hopkins (JH) and Cepheid partnered to translate a robust Quantitative Multiplex Methylation-Specific PCR (QM-MSP) assay to an automated, cartridge-based system that provides quantitative measures of DNA methylation within hours of fine needle aspiration or core biopsy of image-detected suspicious lesions.
METHODS: With a goal of discriminating malignant from benign breast disease with high sensitivity and specificity, we evaluated 24 breast cancer-specific DNA methylation markers (selected through comprehensive methylome analysis) in 119 invasive ductal carcinomas and 186 benign breast tissues. QM-MSP was performed on sections of formalin-fixed paraffin-embedded (FFPE) tissues to quantify DNA methylation. The dynamic range and performance of quantitative methylation detection was tested using a subset of 9 genes in the cartridge-based system.
RESULTS: QM-MSP was performed in a Training set consisting of 93 tissues [n=43 IDC, n=50 benign lesions (25 usual ductal hyperplasia, UDH, and 25 papilloma)] from the US. We selected 9 DNA markers significantly (p<0.05) more methylated in malignant compared to benign lesions, which had low or no methylation. An independent Test set consisted of benign (n=26) and malignant (n=10) tissues (mostly Caucasian; JH Test Set). As a panel, the 9 markers were significantly more methylated in malignant than benign tissue (p<0.001), revealing a sensitivity of 90% and specificity of 92%, using a laboratory cutoff of 9.5 CMI units (900 unit scale) based on receiver operator characteristic statistics (ROC; p<0.0001, AUC=0.977). To determine if the markers characterized in the JH Test Set could perform as well in samples from a different geography, the panel was tested on 176 tissues from Wuhan, China (China Test Set). In this cohort (66 IDC and 110 benign tissues - 49 fibroadenoma, 19 benign cyst, 12 UDH, 30 papilloma), sensitivity was 89% and specificity was 89% for detection of breast cancer with ROC AUC=0.945. An advanced version of the cartridge with up to 12 methylated DNA markers is under development, thus far showing robust signals in cancer and low background in benign tissues. Current work at JH is focused on optimizing the technical performance of the cartridge.
CONCLUSIONS: We identified a panel of methylated DNA markers that discriminate malignant from benign breast lesions and built a prototype automated cartridge-based assay with promising sensitivity and specificity for breast cancer. Such an assay has the potential to aid in specimen triage in the pathology lab and provide fast, low cost and accurate diagnosis of breast cancer in LMIC settings.
Citation Format: Fackler MJ, Downs BM, Mercado-Rodriguez C, Cimino-Mathews A, Chen C, Yuan J, Cope LM, Kohlway A, Kocmond K, Lai E, Weidler J, Visvanathan K, Umbricht CB, Harvey S, Wolff AC, Bates M, Sukumar S. An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-03-07.
Collapse
Affiliation(s)
- MJ Fackler
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - BM Downs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - C Mercado-Rodriguez
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - A Cimino-Mathews
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - C Chen
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - J Yuan
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - LM Cope
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - A Kohlway
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - K Kocmond
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - E Lai
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - J Weidler
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - K Visvanathan
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - CB Umbricht
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - S Harvey
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - AC Wolff
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - M Bates
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| | - S Sukumar
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wuhan University, Wuhan, Hubei, China; Cephied, Sunnyvale, CA
| |
Collapse
|